Evidence map›Paper›PMID 42677093›Full record

ArticleIranian journal of basic medical sciences2026

Bioinformatic analysis and characterization of the anti-CD20 scFv-conjugated Fe

Shabnam Tavangarroosta, Mojgan Bandehpour, Masoumeh Rajabibazl, Farhood Najafi, Sepideh Ghani, Mahmoud Hassani, Bahram Kazemi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shabnam TavangarroostaDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mojgan BandehpourDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Masoumeh RajabibazlDepartment of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farhood NajafiDepartment of Environmental Research, Institute for Color Science and Technology, Tehran, Iran.
Sepideh GhaniCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahmoud HassaniDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Bahram KazemiCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Chronic lymphocytic leukemia (CLL) is one of the common types of leukemia. Various approaches for CLL therapy have been advanced, but they have some adverse effects. Iron oxide (Fe Materials and Methods: The recombinant anti-CD20 scFv was computationally modeled using the AlphaFold server. The complementarity-determining regions (CDR) of scFv were identified using the IMGT/V-Quest database. Molecular docking was performed separately between the scFv antibody and the CD20 antigen (ClusPro 2.0) and between Fe Results: The molecular docking studies revealed favorable interactions between the recombinant scFv antibody and the CD20 antigen. Fe Conclusion: These findings suggest that the Fe

Indexed as

Chronic lymphocytic leukemia (CLL)Iron oxide nanoparticlesMolecular dockingScFv antibody

Identifiers

PMID42677093
PMCPMC13527846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.